C1s Antibody (Polyclonal)
A goat antiserum raised against human C1s protein.
Product Specifications
Citations | 8 |
---|---|
Clonality | Polyclonal |
Immnogen | Highly purified human C1s protein |
Applications | See citations and technical data sheet for application info. |
Concentration | > 40 mg/mL |
Conjugate | Unconjugated |
Cross Reactivity | Human, Baboon |
Ordering Information
Catalog Number | A302 |
---|---|
Catalog Number (CE) | N/A |
Size | 2.0 mL |
Price (USD) | $195.00 |
Price (EURO) | 170,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description | A goat antiserum raised against human C1s protein. |
---|---|
Size | 2.0 mL |
Concentration | > 40 mg/mL |
Applications | See citations and technical data sheet for application info. |
Form | Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide |
Clonality | Polyclonal |
Immunogen | Highly purified human C1s protein |
Conjugate | Unconjugated |
Cross Reactivity | Human, Baboon |
Isotype | Goat IgG |
Purity | N/A |
Source | Goat |
Specificity | The Anti-human C1s polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodifussion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C1s at varying concentrations. |
Storage | Short term (30 days) 4˚C. Long term at or below –20˚C. |
Background | The C1s molecule is a monomeric zymogen protein with a molecular weight of 86 kD. In normal human serum the accepted concentration of C1s is approximately 34 µg/mL. C1s is one of 3 subcomponents that together make the first component of the classical complement pathway, C1. Initiation of the classical complement pathway occurs when C1q binds with IgM or IgG containing antigen-antibody complexes. Upon activation by C1r, the C1s monomer is fragmented into 2 disulfide-linked polypeptide chains, A and B. The enzymatically active site of the C1s molecule is located in the B fragment. With the proteolysis of C1s, C1 becomes active and can then begin to act upon C4 and C2. C1s cleaves C4 into C4a and C4b. C4b then acts as a receptor for C2. Once bound, the C2 becomes a substrate for C1s, which then cleaves C2 into C2a and C2b. C2b remains bound to the C4b creating the C3/C5 convertase of the classical complement pathway. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
Distinct Roles of Classical and Lectin Pathways of Complement in Preeclamptic Placentae. | 2022 | IHC | Human | Placenta Tissue | N/A |
2021 | WB | Human | Retina Tissue | N/A | |
2021 | WB | Human, Mouse | Purified protein | C1q | |
2021 | WB | Mouse | Eye Tissue | Retina, Sodium Iodate-Induced Degeneration | |
Single-cell reconstruction of follicular remodeling in the human adult ovary. | 2019 | IF | Human | Ovary Tissue | Follicular degeneration |
2018 | WB | Human, Mouse | Plasma | Diabetes exosomes | |
Broad Susceptibility of Nucleolar Proteins and Autoantigens to Complement C1 Protease Degradation. | 2017 | WB | Human | HeLa Cells | N/A |
2016 | IHC | Human | Breast Tissue, Colon Tissue, Lung Tissue, Pancreas Tissue, Skin Tissue | Malignant cancer |